Niagen Bioscience
NAGE
59 hedge funds and large institutions have $18.1M invested in Niagen Bioscience in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 8 closing their positions.
256% more call options, than puts
Call options by funds: $146K | Put options by funds: $41K
0.57% more ownership
Funds ownership: 15.27% → 15.84% (+0.57%)
0% more funds holding
Funds holding: 59 → 59 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
5% less capital invested
Capital invested by funds: $19.1M → $18.1M (-$974K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$924K |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$529K |
| 3 |
GI
GAMCO Investors
Greenwich,
Connecticut
|
+$314K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$194K |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
-$349K |
| 2 |
Millennium Management
New York
|
-$267K |
| 3 |
Renaissance Technologies
New York
|
-$256K |
| 4 |
Barclays
London,
United Kingdom
|
-$168K |
| 5 |
BlackRock
New York
|
-$147K |
NAGE Hedge Fund Activity: Q1 2023 in Review
59 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2023, worth a combined $18.1M — down 5.1% from $19.1M a quarter earlier.
Fund positioning in NAGE was balanced in Q1 2023: 8 funds opened new positions, 8 closed out, 16 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $924K. The largest seller was Tieton Capital Management, cutting an estimated $349K.
- 59 institutional investors held Niagen Bioscience (NAGE) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $18.1M of Niagen Bioscience stock for Q1 2023, down 5.1% quarter-over-quarter.
- 8 funds opened new Niagen Bioscience positions in Q1 2023 and 8 closed out, a net change of 0 holders.
- The largest Niagen Bioscience buyer in Q1 2023 was Vanguard Group, an estimated $924K added.
- The largest Niagen Bioscience seller in Q1 2023 was Tieton Capital Management, an estimated $349K sold.
Based on aggregated 13F filings for Q1 2023.